Platelet and Fibrinogen Survival in Calves Implanted with Artificial Heart and Ventricular Assist Device -Correlation with Autopsy Findings

Hamid Al-Mondhiry; Walter E Pae; Cynthia A Miller; William S Pierce

doi:10.1055/s-0038-1648462

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1992; 67(04): 413-416
DOI: 10.1055/s-0038-1648462

Original Articles

Schattauer GmbH Stuttgart

Platelet and Fibrinogen Survival in Calves Implanted with Artificial Heart and Ventricular Assist Device -Correlation with Autopsy Findings

Hamid Al-Mondhiry

The Departments of Medicine and Surgery, The Pennsylvania State University, College of Medicine, The Milton S. Hershey Medical Center, Hershey, PA, USA

,

Walter E Pae

The Departments of Medicine and Surgery, The Pennsylvania State University, College of Medicine, The Milton S. Hershey Medical Center, Hershey, PA, USA

,

Cynthia A Miller

The Departments of Medicine and Surgery, The Pennsylvania State University, College of Medicine, The Milton S. Hershey Medical Center, Hershey, PA, USA

,

William S Pierce

The Departments of Medicine and Surgery, The Pennsylvania State University, College of Medicine, The Milton S. Hershey Medical Center, Hershey, PA, USA

› Author Affiliations

Abstract

PDF Download

Summary

The two main ingredients of blood clots formed on artificial surface are platelets and fibrinogen. In this study, we measured platelet and fibrinogen survival in calves implanted with total artificial heart (TAH) and left ventricular assist device (LVAD), and correlate these data with autopsy findings. Platelet survival with autologous ¹¹¹In-labeled platelets was performed on nine calves implanted with TAH and five with LVAD. Fibrinogen survival with ¹³¹I-labeled homologous fibrinogen was performed on six calves with TAH and three with LVAD. Platelet survival was significantly shortened in both groups of animals: 5.89 ± 0.52 days, control 6.46 ± 0.31 days, p = 0.0013; fibrinogen survival was normal: 8.79 ± 1.20 days, control 8.64 ± 1.16 days. At autopsy two calves with TAH had multiorgan thromboembolism. Two other animals with TAH and four with LVAD had focal renal infarcts. Most animals had minor clot formation within the prosthetic device. Major septic complications occurred in four calves with TAH and one with LVAD. Continuous platelet activation by artificial surface probably explains the shortened platelet survival and thromboembolic complications.

PDF (809 kb)

References

References
1 Salzman EW, Merrill EW. Interaction of blood with artificial surfaces. In: Hemostasis and Thrombosis. 2nd. edition Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds) J. B. Lippincott; Philadelphia, PA: 1987. pp 1335-1347
2 Clagett GP. Artificial devices in clinical practice. In: Hemostasis and Thrombosis. 2nd edition. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds) J. B. Lippincott; Philadelphia, PA: 1987. pp 1348-1365
3 Baier RE, Dutton RC. Initial events in interactions of blood with a foreign surface. J Biomed Mater Res 1969; 3: 191-206
4 Scarborough DE, Mason RG, Dalldorf PG, Brinkhous KM. Morphological manifestations of blood-solid interfacial reactions: A scanning and transmission electron microscopic study. Lab Invest 1969; 20: 164-169
5 Packham MA, Evans G, Glynn MF, Mustard JF. The effect of plasma proteins on the interaction of platelets with glass surfaces. J Lab Clin Med 1969; 73: 686-697
6 Zucker MG, Vroman L. Platelet adhesion induced by fibrinogen adsorbed onto glass. Soc Exp Biol Med 1969; 131: 318-320
7 Salzman EW, Lindon J, McManama G, Ware JA. Role of fibrinogen in activation of platelets by artificial surfaces. Ann NY Acad Sci 1987; 516: 184-199
8 Cross MJ. Effect of fibrinogen on the aggregation of platelets by adenosine diphosphate. Thromb Diath Haemorrh 1964; 12: 524-527
9 Niewiarowski S, Budzynski AZ, Lipinski B. Significance of the intact polypeptide chains of human fibrinogen in ADP-induced platelet aggregation. Blood 1977; 49: 635-644
10 Harker LA, Slichter SJ. Platelet and fibrinogen consumption in man. N Engl J Med 1972; 287: 999-1005
11 Green R, Liska J, Egberg N, Koul B, Ljungberg B, Blomback M, Vesterqvist O, Semb B. Hemostatic disturbances associated with implantation of an artificial heart. Thromb Res 1987; 48: 349-362
12 Ring ME, Feinberg WM, Levinson MM, Bruck DC, Smith RG, Icenogle TM, Copeland JG. Platelet and fibrin metabolism in recipients of the Jarvik 7 total artificial heart. J Heart Transplant 1989; 8: 225-232
13 Al-Mondhiry H, Pierce WS. Hemostatic abnormalities in two patients implanted with total artificial hearts. Artif Organs 1989; 13: 464-469
14 Nossel HL, Ti M, Kaplan KL, Spandonis K, Soland T, Butler Jr VP. The generation of fibrinopeptide A in clinical blood samples. Evidence for thrombin activity. J Clin Invest 1976; 58: 1136-1144
15 Kaplan KL, Owen J. Plasma levels of betathromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981; 57: 199-202
16 Al-Mondhiry H, Pae W, Rosenberg G, Pierce W. Hematologic abnormalities and thromboembolic complications in calves implanted with pneumatic artificial hearts. Long-term studies and autopsy findings. Trans Am Soc Artif Organs 1989; 35: 238-241
17 Pierce WS, Donachy JH, Landis DL, Brighton JA, Rosenberg G, Migllore JJ, Prophet GA, White WJ, Waldhausen HA. Prolonged mechanical support of the left ventricle. Circulation 1978; 58 (Suppl) (01) 1-133-1-146
18 Pierce WS, Parr GVS, Myers JL, Pae Jr WE, Bull A, Waldhaussen JA. Ventricular assist pumping in patients with cardiogenic shock after cardiac operations. N Engl J Med 1981; 305: 1606-1610
19 Shaffer LJ, Donachy JH, Rosenberg G. et al Total artificial heart implantation in calves with pump of an angled port design. ASAIO Trans 1979; 25: 254-259
20 Pierce WS, Myers JL, Donachy JH. et al Approaches to the artificial heart. Surgery 1981; 90: 137-148
21 Takeda Y. Studies of the metabolism and distribution of fibrinogen in healthy men with autologous ¹²⁵I-labeled fibrinogen. J Clin Invest 1966; 45: 103-111
22 Marchalonis JJ. An enzymatic method for the trace iodination of immunoglobulins and other proteins. Biochem J 1969; 113: 299-305
23 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestim-mung des Fibrinogens. Acta Hematol 1957; 17: 237-246
24 Al-Mondhiry H, Pierce WS, Richenbacher W. Platelet survival and function in animals with prosthetic mitral valve: The effect of nafazatrom. Thromb Hemostas 1984; 52: 99-101
25 Riba AL, Thakur ML, Gottschalk A, Andriole VT, Zaret BL. Imaging experimental infective endocarditis with Indium-111 labeled blood cellular components. Circulation 1978; 59: 336-343
26 Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979; 254: 5337-5363
27 Knudson DL, Buckley SM. Invertebrate cell culture methods for the study of invertebrate-associated animal viruses. In: Methods in Virology. Maramorsch K, Kaprowski H. (eds) Academic Press; New York: 1977. p 345
28 Scheffell U, McIntyre PA, Evatt B, Dvornicky Jr JA, Natarayan TK, Bolling DR, Murphy EH. Evaluation of Indium-111 as a new high photon yield gamma emitting “physiological” platelet label. Johns Hopkins Med J 1977; 140: 285-293
29 Spero JA, Lewis JH, Hasiba U. Disseminated intravascular coagulation findings in 346 patients. Thromb Haemostas 1980; 43: 28-33
30 Colucci M, Parmo JA, Collen D. Generation in plasma of a fast acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-824
31 Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79: 124-130
32 Miiller-Berghaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemostas 1989; 15: 58-87
33 Philippe J, Offner F, Declerck PJ, Leroux-Roels G, Vogelaers D, Baele G, Collen D. Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemostas 1991; 65: 291-295